Christine M. Lovly

18.4k citations

143 papers · 6.8k indexed · 3 hit papers · h-index 44

Oncology top 0.5%
- Lung Cancer Research Studies 39
- Cancer Immunotherapy and Biomarkers 12
- Pancreatic and Hepatic Oncology Research 10
Cancer Research top 1%
- Cancer Genomics and Diagnostics 44
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 89
Molecular Biology top 2%
- Cancer therapeutics and mechanisms 20
- Melanoma and MAPK Pathways 10
Pathology and Forensic Medicine top 2%
Epidemiology
- Neuroendocrine Tumor Research Advances 11

Co-authors: Zhenfang Du Alice T. Shaw David Westover Wade T. Iams William Pao J. Zugazagoitia Luis Paz‐Ares Byoung Chul Cho
Cited by: Oncology Cancer Research Pulmonary and Respiratory Medicine
Journals: Proceedings of the National Academy of Sciences (2 papers)Nature Medicine (2 papers)Nature Communications (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Christine M. Lovly

136 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Christine M. Lovly

Since Specialization

Citations

This map shows the geographic impact of Christine M. Lovly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine M. Lovly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine M. Lovly more than expected).

Fields of papers citing papers by Christine M. Lovly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine M. Lovly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine M. Lovly. The network helps show where Christine M. Lovly may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christine M. Lovly, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christine M. Lovly Line = papers co-authored together Christine M. Lovly links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PP01.115 Real-World Characteristics and Outcomes Among Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Mutations Journal of Thoracic Oncology ·Christina S. Baik,Xiuning Le,Christine M. Lovly,Tejas Patil,Sonia S. Maruti,Stephen A. Stanhope,Stephan Herbertz,Misako Nagasaka	2024	1
2	1298P Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD) Annals of Oncology ·X. Le,C.S. Baik,Misako Nagasaka,Tejas Patil,Sonia S. Maruti,S. Stanhope,Nurettin Kaya,Stephan Herbertz,Christine M. Lovly	2024	1
3	Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics Protein Science ·Claiborne W. Tydings,Bhuminder Singh,Adam W. Smith,Kaitlyn V. Ledwitch,Benjamin P. Brown,Christine M. Lovly,Allison S. Walker,Jens Meiler	2024	3
4	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformationbreakdown → Cancer Discovery ·Smruthy Sivakumar,Jay A. Moore,Meagan Montesion,Radwa Sharaf,Douglas I. Lin,Caterina I. Colón,Zoe Fleishmann,Ericka M. Ebot,Justin Y. Newberg,Jennifer M. Mills,Priti Hegde,Quintin Pan,Afshin Dowlati,Garrett M. Frampton,Julien Sage,Christine M. Lovly	2023	75
5	My Cancer Genome: Coevolution of Precision Oncology and a Molecular Oncology Knowledgebase JCO Clinical Cancer Informatics ·Marilyn Holt,Kathleen F. Mittendorf,Michele L. Lenoue-Newton,Neha Jain,Ingrid Anderson,Christine M. Lovly,Travis Osterman,Christine Micheel,Mia Levy	2021	19
6	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation Clinical Cancer Research ·Benjamin P. Brown,Yunkai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Christine M. Lovly	2019	76
7	ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties Molecular Cancer Research ·Merrida Childress,Stephen M. Himmelberg,Huiqin Chen,Wanleng Deng,Michael A. Davies,Christine M. Lovly	2018	76
8	Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study Clinical Cancer Research ·Leora Horn,Jeffrey R. Infante,Karen L. Reckamp,George R. Blumenschein,Ticiana Leal,Saiama N. Waqar,Barbara J. Gitlitz,Rachel E. Sanborn,Jennifer G. Whisenant,Liping Du,Joel W. Neal,Jon P. Gockerman,Gary Dukart,Kimberly Harrow,Chris Liang,James J. Gibbons,Allison Holzhausen,Christine M. Lovly,Heather A. Wakelee	2018	131
9	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer Cancer Research ·Eiki Ichihara,David Westover,Catherine B. Meador,Yingjun Yan,Joshua A. Bauer,Lu Wang,Fei Ye,Amanda Kulick,Elisa de Stanchina,Robert McEwen,Marc Ladanyi,Darren A.E. Cross,William Pao,Christine M. Lovly	2017	104
10	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy Pigment Cell & Melanoma Research ·Douglas B. Johnson,Merrida Childress,Zachary R. Chalmers,Garrett M. Frampton,Siraj M. Ali,Samuel M. Rubinstein,David Fabrizio,Jeffrey S. Ross,Sohail Balasubramanian,Vincent A. Miller,Philip J. Stephens,Jeffrey A. Sosman,Christine M. Lovly	2017	28
11	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer Cancer Research ·Katherine Amato,Shan Wang,Li Tan,Andrew K. Hastings,Wenqiang Song,Christine M. Lovly,Catherine B. Meador,Fei Ye,Lu Wang,Justin M. Balko,Daniel C. Colvin,Justin Cates,William Pao,Nathanael S. Gray,Jin Chen	2016	84
12	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies Cancer Immunology Research ·Douglas B. Johnson,Christine M. Lovly,Marisa Flavin,Katherine S. Panageas,Gregory D. Ayers,Zhiguo Zhao,Wade T. Iams,Marta Colgan,Sarah DeNoble,Charles R. Terry,Elizabeth Berry,A. John Iafrate,Ryan J. Sullivan,Richard D. Carvajal,Jeffrey A. Sosman	2015	132
13	EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib Cancer Discovery ·Jean‐Nicolas Gallant,Jonathan H. Sheehan,Timothy M. Shaver,Mark Bailey,Doron Lipson,Raghu Chandramohan,Monica Red Brewer,Sally J. York,Mark G. Kris,Jennifer A. Pietenpol,Marc Ladanyi,Vincent A. Miller,Siraj M. Ali,Jens Meiler,Christine M. Lovly	2015	81
14	Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer Molecular Cancer Therapeutics ·Catherine B. Meador,Hailing Jin,Elisa de Stanchina,Caroline A. Nebhan,Valentina Pirazzoli,Lu Wang,Huy Gia Vuong,Katherine E. Hutchinson,Peilin Jia,Xi Chen,Rosana Eisenberg,Marc Ladanyi,Katerina Politi,Zhongming Zhao,Christine M. Lovly,Darren A.E. Cross,William Pao	2014	22
15	MAP2K1 ( MEK1 ) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking Clinical Cancer Research ·Maria E. Arcila,Alexander Drilon,Brooke E. Sylvester,Christine M. Lovly,Laetitia Borsu,Boris Reva,Mark G. Kris,David B. Solit,Marc Ladanyi	2014	106
16	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions Cancer Discovery ·Christine M. Lovly,Abha A. Gupta,Doron Lipson,Geoff Otto,Tina Brennan,Catherine T. Chung,Scott C. Borinstein,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Cheryl M. Coffin	2014	303
17	Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Cancer Discovery ·Jim Sang,Jaime Acquaviva,Julie C. Friedland,Donald L. Smith,Manuel Sequeira,Chaohua Zhang,Qin Jiang,Liquan Xue,Christine M. Lovly,John-Paul Jimenez,Alice T. Shaw,Robert C. Doebele,Suqin He,Richard C. Bates,D. Ross Camidge,Stephan W. Morris,Iman El‐Hariry,David A. Proia	2013	174
18	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants Clinical Cancer Research ·Johannes M. Heuckmann,Hyatt Balke‐Want,Florian Malchers,Martin Peifer,Martin L. Sos,Mirjam Koker,Lydia Meder,Christine M. Lovly,Lukas C. Heukamp,William Pao,Ralf Küppers,Roman K. Thomas	2012	201
19	Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors Cancer Research ·Christine M. Lovly,Johannes M. Heuckmann,Elisa de Stanchina,Heidi Chen,Roman K. Thomas,Chris Liang,William Pao	2011	177
20	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors Clinical Cancer Research ·Johannes M. Heuckmann,Michael Hölzel,Martin L. Sos,Stefanie Heynck,Hyatt Balke‐Want,Mirjam Koker,Martin Peifer,Jonathan M. Weiss,Christine M. Lovly,Christian Grütter,Daniel Rauh,William Pao,Roman K. Thomas	2011	147

About Christine M. Lovly

Christine M. Lovly is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 6.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (89 papers), Cancer Genomics and Diagnostics (44 papers), Lung Cancer Research Studies (39 papers), Cancer therapeutics and mechanisms (20 papers), Cancer Immunotherapy and Biomarkers (12 papers), Neuroendocrine Tumor Research Advances (11 papers), Melanoma and MAPK Pathways (10 papers) and Pancreatic and Hepatic Oncology Research (10 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (1.4k citations) and Pulmonary and Respiratory Medicine (3.1k citations). Christine M. Lovly has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Zhenfang Du, Alice T. Shaw, David Westover, Wade T. Iams, William Pao, J. Zugazagoitia, Luis Paz‐Ares, Byoung Chul Cho, Helen Piwnica‐Worms and Ryohei Katayama. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact